CHRS COHERUS ONCOLOGY INC
2026Q2 · CUSIP 19249H103 · Sector: Healthcare & Biotech
Funds leaving and price falling — historically weak for the next six months
144 funds held CHRS at the end of 2026Q2, down 13 from the quarter before. Buying is stronger than only 10.7% of US stocks, and the price fell over the same quarter — funds leaving and price weakness at the same time. CHRS has had 7 buying rushes in its history, and the price moved -14.2% on average over the six months after (that is the raw price move, not how much it beat the market by). It sits in the Healthcare & Biotech sector.
How many funds owned it, quarter by quarter
Bars = net change in institutional holders, positive (green) or negative (red). Line = total institutional holders.
What happened after each past buying rush 7 times in its history
| Quarter of the rush | How unusual then | Price, next 3 months | Price, next 6 months |
|---|---|---|---|
| 2026Q1 | Top 20% | — | — |
| 2019Q3 | Top 10% | +17.3% | -10.1% |
| 2019Q2 | Top 5% | +0.5% | +17.4% |
| 2016Q3 | Top 5% | -18.8% | -19.5% |
| 2015Q3 | Top 20% | -46.4% | -28.4% |
| 2015Q2 | Top 20% | -19.2% | -53.6% |
| 2015Q1 | Top 20% | +35.0% | +9.1% |
These are the raw price moves, not how much it beat the market by. Compare them against the market over the same months — in a strong bull market almost everything is up.
Show all the numbers (large funds, value held, options…) ▾ Collapse ▴
These are for people who want to dig. Skip them if they do not mean anything to you — the three numbers above are enough.
8,697 institutions have filed for this quarter. 13F permits late filing and a small number arrive in the weeks after the deadline, so the holder counts and changes below may tick up.
Email me the next update
2026 Q3 holdings are due 2026-11-16. We will email you when the refreshed lists are live.